{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": -0.7936538, "regularMarketPrice": 6.25, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.74, "epsForward": -2.7, "epsCurrentYear": -2.95, "priceEpsCurrentYear": -2.118644, "sharesOutstanding": 61838600, "bookValue": 2.302, "fiftyDayAverage": 6.112, "fiftyDayAverageChange": 0.13800001, "fiftyDayAverageChangePercent": 0.022578536, "twoHundredDayAverage": 5.18845, "twoHundredDayAverageChange": 1.0615501, "twoHundredDayAverageChangePercent": 0.20459871, "marketCap": 395731264, "forwardPE": -2.3148148, "priceToBook": 2.7150304, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.9 - Buy", "tradeable": false, "cryptoTradeable": false, "exchange": "FRA", "shortName": "MACROGENICS INC.  DL-,01", "longName": "MacroGenics, Inc.", "messageBoardId": "finmb_600911", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1382335200000, "priceHint": 2, "regularMarketChange": -0.05000019, "regularMarketTime": 1683871215, "regularMarketDayHigh": 6.25, "regularMarketDayRange": "6.25 - 6.25", "regularMarketDayLow": 6.25, "regularMarketVolume": 300, "regularMarketPreviousClose": 6.3, "bid": 6.3, "ask": 6.4, "bidSize": 200, "askSize": 200, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 6.25, "averageDailyVolume3Month": 202, "averageDailyVolume10Day": 80, "fiftyTwoWeekLowChange": 4.1099997, "fiftyTwoWeekLowChangePercent": 1.9205605, "fiftyTwoWeekRange": "2.14 - 7.05", "fiftyTwoWeekHighChange": -0.8000002, "fiftyTwoWeekHighChangePercent": -0.1134752, "fiftyTwoWeekLow": 2.14, "fiftyTwoWeekHigh": 7.05, "earningsTimestamp": 1683664200, "earningsTimestampStart": 1691405940, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "symbol": "M55.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "9704 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "301 251 5172", "fax": "301 251 5321", "website": "https://www.macrogenics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 \u00d7 CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B \u00d7 CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 357, "companyOfficers": [{"maxAge": 1, "name": "Dr. Scott  Koenig M.D., Ph.D.", "age": 70, "title": "Pres, CEO & Director", "yearBorn": 1952, "fiscalYear": 2022, "totalPay": {"raw": 1059292, "fmt": "1.06M", "longFmt": "1,059,292"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. James  Karrels", "age": 55, "title": "Sr. VP, CFO & Corp. Sec.", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 626829, "fmt": "626.83k", "longFmt": "626,829"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Eric Blasius Risser", "age": 49, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 651362, "fmt": "651.36k", "longFmt": "651,362"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Thomas M. Spitznagel Ph.D.", "age": 55, "title": "Sr. VP of Technical Operations", "yearBorn": 1967, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ezio  Bonvini", "age": 68, "title": "Sr. VP of Research & Chief Scientific Officer", "yearBorn": 1954, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jeffrey Stuart Peters", "age": 51, "title": "Sr. VP, Gen. Counsel & Corp. Compliance Officer", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Stephen L. Eck M.D., Ph.D.", "age": 67, "title": "Sr. VP of Clinical Devel. & Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lynn  Cilinski", "age": 64, "title": "VP, Controller & Treasurer", "yearBorn": 1958, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 5, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}